Decursin alleviates the aggravation of osteoarthritis via inhibiting PI3K-Akt and NF-kB signal pathway

•Decursin could improve the progression of osteoarthritis by inhibiting inflammatory reaction.•The molecular docking analysis showed that DE has a strong binding affinity with the inhibitory targets of PI3K.•Decursin may be a potential agent in treatment of osteoarthritis. Osteoarthritis (OA) is a c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International immunopharmacology 2021-08, Vol.97, p.107657-107657, Article 107657
Hauptverfasser: He, Linjie, Pan, Yinan, Yu, Jiapei, Wang, Ben, Dai, Gaole, Ying, Xiaozhou
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 107657
container_issue
container_start_page 107657
container_title International immunopharmacology
container_volume 97
creator He, Linjie
Pan, Yinan
Yu, Jiapei
Wang, Ben
Dai, Gaole
Ying, Xiaozhou
description •Decursin could improve the progression of osteoarthritis by inhibiting inflammatory reaction.•The molecular docking analysis showed that DE has a strong binding affinity with the inhibitory targets of PI3K.•Decursin may be a potential agent in treatment of osteoarthritis. Osteoarthritis (OA) is a common joint disease that takes joint degeneration or aging as its pathological basis, and joint swelling, pain or dysfunction as its main clinical manifestations. Decursin (DE), the major active component isolated from Angelica gigas Nakai, has been demonstrated to possess anti-inflammatory effect in many diseases. But, the specific physiological mechanism of DE on OA is not clear yet. Therefore, the object of this study was to assess the therapeutic effect of DE on OA, and to explore its potential anti-inflammatory mechanisms. In vitro cell experiments, the inflammatory response in chondrocytes is mediated via interleukin-1β (IL-1β), which led to abnormal secretion of pro-inflammatory factors, such as prostaglandin E2 (PGE2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), cyclooxygenase-2 (COX-2), nitric oxide (NO) and inducible nitric oxide synthase (iNOS). These cytokines were all decreased by the preconditioning of DE in a dose-dependent form of 1, 5, and 10 µM. Moreover, DE could restrain IL-1β-mediated inflammatory reaction and the collapse of extracellular matrix (ECM) via reducing the secretion of ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) and MMPs (matrix metalloproteinases). In short, DE restrained IL-1β-mediated abnormal excitation of PI3K/AKT/NF-κB axis. Furthermore, molecular docking analysis showed that DE has a strong binding affinity with the inhibitory targets of PI3K. In vivo animal studies, DE treatment could helped to improve destruction of articular cartilage and decreased the serum inflammatory factor levels in an operationally induced mouse OA model. To sum up, these data obtained from the experiment indicate that DE has good prospects for the treatment of osteoarthritis.
doi_str_mv 10.1016/j.intimp.2021.107657
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2516227198</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576921002939</els_id><sourcerecordid>2568032473</sourcerecordid><originalsourceid>FETCH-LOGICAL-c390t-a57390429d6452855d49584da58022372a70b87f0965b3b246387a01b6ef63dd3</originalsourceid><addsrcrecordid>eNp9kctu1DAUhi0Eohd4A4QssWGTwXcnG6RSWqiogAWsLSc-mfE0Y09tZ1DfHo9SWLBgdS76zvVH6BUlK0qoerdd-VD8br9ihNGa0krqJ-iUtrptqCbyafWl0o3UqjtBZzlvCal5QZ-jE84rJYU4ReNHGOaUfcB2muDgbYGMywawXa-TPdjiY8BxxDEXiDaVTfLFZ1xB7MPG9zUKa_z9hn9pLu4KtsHhr9fN3Qec_TrYCe9t2fyyDy_Qs9FOGV4-2nP08_rqx-Xn5vbbp5vLi9tm4B0pjZW6WsE6p4RkrZROdLIVzsqWMMY1s5r0rR5Jp2TPeyZUPcQS2isYFXeOn6O3S999ivcz5GJ2Pg8wTTZAnLNhkirGNO3air75B93GOdWdj5RqCWdC80qJhRpSzDnBaPbJ72x6MJSYow5maxYdzFEHs-hQy14_Np_7Hbi_RX8eX4H3CwD1GwcPyeTBQxjA-QRDMS76_0_4DSrsmR8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2568032473</pqid></control><display><type>article</type><title>Decursin alleviates the aggravation of osteoarthritis via inhibiting PI3K-Akt and NF-kB signal pathway</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>He, Linjie ; Pan, Yinan ; Yu, Jiapei ; Wang, Ben ; Dai, Gaole ; Ying, Xiaozhou</creator><creatorcontrib>He, Linjie ; Pan, Yinan ; Yu, Jiapei ; Wang, Ben ; Dai, Gaole ; Ying, Xiaozhou</creatorcontrib><description>•Decursin could improve the progression of osteoarthritis by inhibiting inflammatory reaction.•The molecular docking analysis showed that DE has a strong binding affinity with the inhibitory targets of PI3K.•Decursin may be a potential agent in treatment of osteoarthritis. Osteoarthritis (OA) is a common joint disease that takes joint degeneration or aging as its pathological basis, and joint swelling, pain or dysfunction as its main clinical manifestations. Decursin (DE), the major active component isolated from Angelica gigas Nakai, has been demonstrated to possess anti-inflammatory effect in many diseases. But, the specific physiological mechanism of DE on OA is not clear yet. Therefore, the object of this study was to assess the therapeutic effect of DE on OA, and to explore its potential anti-inflammatory mechanisms. In vitro cell experiments, the inflammatory response in chondrocytes is mediated via interleukin-1β (IL-1β), which led to abnormal secretion of pro-inflammatory factors, such as prostaglandin E2 (PGE2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), cyclooxygenase-2 (COX-2), nitric oxide (NO) and inducible nitric oxide synthase (iNOS). These cytokines were all decreased by the preconditioning of DE in a dose-dependent form of 1, 5, and 10 µM. Moreover, DE could restrain IL-1β-mediated inflammatory reaction and the collapse of extracellular matrix (ECM) via reducing the secretion of ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) and MMPs (matrix metalloproteinases). In short, DE restrained IL-1β-mediated abnormal excitation of PI3K/AKT/NF-κB axis. Furthermore, molecular docking analysis showed that DE has a strong binding affinity with the inhibitory targets of PI3K. In vivo animal studies, DE treatment could helped to improve destruction of articular cartilage and decreased the serum inflammatory factor levels in an operationally induced mouse OA model. To sum up, these data obtained from the experiment indicate that DE has good prospects for the treatment of osteoarthritis.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2021.107657</identifier><identifier>PMID: 33878544</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>1-Phosphatidylinositol 3-kinase ; ADAM protein ; Aging ; AKT protein ; Animals ; Anti-Inflammatory Agents - pharmacology ; Anti-Inflammatory Agents - therapeutic use ; Arthritis ; Benzopyrans - pharmacology ; Benzopyrans - therapeutic use ; Biomedical materials ; Butyrates - pharmacology ; Butyrates - therapeutic use ; Cartilage ; Cartilage (articular) ; Cartilage diseases ; Cartilage, Articular - drug effects ; Cartilage, Articular - immunology ; Cartilage, Articular - pathology ; Chondrocyte ; Chondrocytes ; Cyclooxygenase-2 ; Cytokines ; Decursin ; Degeneration ; Disease Progression ; Drug Evaluation, Preclinical ; Extracellular matrix ; Health services ; Humans ; IL-1β ; In vivo methods and tests ; Inflammatory ; Inflammatory response ; Interleukin 6 ; Interleukin-1beta - metabolism ; Joint diseases ; Male ; Matrix metalloproteinase ; Matrix metalloproteinases ; Mice ; Molecular docking ; Molecular Docking Simulation ; NF-kappa B - metabolism ; NF-κB ; NF-κB protein ; Nitric oxide ; Nitric-oxide synthase ; Osteoarthritis ; Osteoarthritis - drug therapy ; Osteoarthritis - immunology ; Osteoarthritis - pathology ; Pain ; Phosphatidylinositol 3-Kinases - metabolism ; Physiological effects ; PI3K ; Preconditioning ; Prostaglandin E2 ; Proto-Oncogene Proteins c-akt - metabolism ; Signal Transduction - drug effects ; Signal Transduction - immunology ; Thrombospondin ; Tumor necrosis factor-TNF ; Tumor necrosis factor-α</subject><ispartof>International immunopharmacology, 2021-08, Vol.97, p.107657-107657, Article 107657</ispartof><rights>2021 Elsevier B.V.</rights><rights>Copyright © 2021 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier BV Aug 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c390t-a57390429d6452855d49584da58022372a70b87f0965b3b246387a01b6ef63dd3</citedby><cites>FETCH-LOGICAL-c390t-a57390429d6452855d49584da58022372a70b87f0965b3b246387a01b6ef63dd3</cites><orcidid>0000-0003-0979-7207</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2021.107657$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27926,27927,45997</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33878544$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>He, Linjie</creatorcontrib><creatorcontrib>Pan, Yinan</creatorcontrib><creatorcontrib>Yu, Jiapei</creatorcontrib><creatorcontrib>Wang, Ben</creatorcontrib><creatorcontrib>Dai, Gaole</creatorcontrib><creatorcontrib>Ying, Xiaozhou</creatorcontrib><title>Decursin alleviates the aggravation of osteoarthritis via inhibiting PI3K-Akt and NF-kB signal pathway</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>•Decursin could improve the progression of osteoarthritis by inhibiting inflammatory reaction.•The molecular docking analysis showed that DE has a strong binding affinity with the inhibitory targets of PI3K.•Decursin may be a potential agent in treatment of osteoarthritis. Osteoarthritis (OA) is a common joint disease that takes joint degeneration or aging as its pathological basis, and joint swelling, pain or dysfunction as its main clinical manifestations. Decursin (DE), the major active component isolated from Angelica gigas Nakai, has been demonstrated to possess anti-inflammatory effect in many diseases. But, the specific physiological mechanism of DE on OA is not clear yet. Therefore, the object of this study was to assess the therapeutic effect of DE on OA, and to explore its potential anti-inflammatory mechanisms. In vitro cell experiments, the inflammatory response in chondrocytes is mediated via interleukin-1β (IL-1β), which led to abnormal secretion of pro-inflammatory factors, such as prostaglandin E2 (PGE2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), cyclooxygenase-2 (COX-2), nitric oxide (NO) and inducible nitric oxide synthase (iNOS). These cytokines were all decreased by the preconditioning of DE in a dose-dependent form of 1, 5, and 10 µM. Moreover, DE could restrain IL-1β-mediated inflammatory reaction and the collapse of extracellular matrix (ECM) via reducing the secretion of ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) and MMPs (matrix metalloproteinases). In short, DE restrained IL-1β-mediated abnormal excitation of PI3K/AKT/NF-κB axis. Furthermore, molecular docking analysis showed that DE has a strong binding affinity with the inhibitory targets of PI3K. In vivo animal studies, DE treatment could helped to improve destruction of articular cartilage and decreased the serum inflammatory factor levels in an operationally induced mouse OA model. To sum up, these data obtained from the experiment indicate that DE has good prospects for the treatment of osteoarthritis.</description><subject>1-Phosphatidylinositol 3-kinase</subject><subject>ADAM protein</subject><subject>Aging</subject><subject>AKT protein</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Arthritis</subject><subject>Benzopyrans - pharmacology</subject><subject>Benzopyrans - therapeutic use</subject><subject>Biomedical materials</subject><subject>Butyrates - pharmacology</subject><subject>Butyrates - therapeutic use</subject><subject>Cartilage</subject><subject>Cartilage (articular)</subject><subject>Cartilage diseases</subject><subject>Cartilage, Articular - drug effects</subject><subject>Cartilage, Articular - immunology</subject><subject>Cartilage, Articular - pathology</subject><subject>Chondrocyte</subject><subject>Chondrocytes</subject><subject>Cyclooxygenase-2</subject><subject>Cytokines</subject><subject>Decursin</subject><subject>Degeneration</subject><subject>Disease Progression</subject><subject>Drug Evaluation, Preclinical</subject><subject>Extracellular matrix</subject><subject>Health services</subject><subject>Humans</subject><subject>IL-1β</subject><subject>In vivo methods and tests</subject><subject>Inflammatory</subject><subject>Inflammatory response</subject><subject>Interleukin 6</subject><subject>Interleukin-1beta - metabolism</subject><subject>Joint diseases</subject><subject>Male</subject><subject>Matrix metalloproteinase</subject><subject>Matrix metalloproteinases</subject><subject>Mice</subject><subject>Molecular docking</subject><subject>Molecular Docking Simulation</subject><subject>NF-kappa B - metabolism</subject><subject>NF-κB</subject><subject>NF-κB protein</subject><subject>Nitric oxide</subject><subject>Nitric-oxide synthase</subject><subject>Osteoarthritis</subject><subject>Osteoarthritis - drug therapy</subject><subject>Osteoarthritis - immunology</subject><subject>Osteoarthritis - pathology</subject><subject>Pain</subject><subject>Phosphatidylinositol 3-Kinases - metabolism</subject><subject>Physiological effects</subject><subject>PI3K</subject><subject>Preconditioning</subject><subject>Prostaglandin E2</subject><subject>Proto-Oncogene Proteins c-akt - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Signal Transduction - immunology</subject><subject>Thrombospondin</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumor necrosis factor-α</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1DAUhi0Eohd4A4QssWGTwXcnG6RSWqiogAWsLSc-mfE0Y09tZ1DfHo9SWLBgdS76zvVH6BUlK0qoerdd-VD8br9ihNGa0krqJ-iUtrptqCbyafWl0o3UqjtBZzlvCal5QZ-jE84rJYU4ReNHGOaUfcB2muDgbYGMywawXa-TPdjiY8BxxDEXiDaVTfLFZ1xB7MPG9zUKa_z9hn9pLu4KtsHhr9fN3Qec_TrYCe9t2fyyDy_Qs9FOGV4-2nP08_rqx-Xn5vbbp5vLi9tm4B0pjZW6WsE6p4RkrZROdLIVzsqWMMY1s5r0rR5Jp2TPeyZUPcQS2isYFXeOn6O3S999ivcz5GJ2Pg8wTTZAnLNhkirGNO3air75B93GOdWdj5RqCWdC80qJhRpSzDnBaPbJ72x6MJSYow5maxYdzFEHs-hQy14_Np_7Hbi_RX8eX4H3CwD1GwcPyeTBQxjA-QRDMS76_0_4DSrsmR8</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>He, Linjie</creator><creator>Pan, Yinan</creator><creator>Yu, Jiapei</creator><creator>Wang, Ben</creator><creator>Dai, Gaole</creator><creator>Ying, Xiaozhou</creator><general>Elsevier B.V</general><general>Elsevier BV</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0979-7207</orcidid></search><sort><creationdate>202108</creationdate><title>Decursin alleviates the aggravation of osteoarthritis via inhibiting PI3K-Akt and NF-kB signal pathway</title><author>He, Linjie ; Pan, Yinan ; Yu, Jiapei ; Wang, Ben ; Dai, Gaole ; Ying, Xiaozhou</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c390t-a57390429d6452855d49584da58022372a70b87f0965b3b246387a01b6ef63dd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>1-Phosphatidylinositol 3-kinase</topic><topic>ADAM protein</topic><topic>Aging</topic><topic>AKT protein</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Arthritis</topic><topic>Benzopyrans - pharmacology</topic><topic>Benzopyrans - therapeutic use</topic><topic>Biomedical materials</topic><topic>Butyrates - pharmacology</topic><topic>Butyrates - therapeutic use</topic><topic>Cartilage</topic><topic>Cartilage (articular)</topic><topic>Cartilage diseases</topic><topic>Cartilage, Articular - drug effects</topic><topic>Cartilage, Articular - immunology</topic><topic>Cartilage, Articular - pathology</topic><topic>Chondrocyte</topic><topic>Chondrocytes</topic><topic>Cyclooxygenase-2</topic><topic>Cytokines</topic><topic>Decursin</topic><topic>Degeneration</topic><topic>Disease Progression</topic><topic>Drug Evaluation, Preclinical</topic><topic>Extracellular matrix</topic><topic>Health services</topic><topic>Humans</topic><topic>IL-1β</topic><topic>In vivo methods and tests</topic><topic>Inflammatory</topic><topic>Inflammatory response</topic><topic>Interleukin 6</topic><topic>Interleukin-1beta - metabolism</topic><topic>Joint diseases</topic><topic>Male</topic><topic>Matrix metalloproteinase</topic><topic>Matrix metalloproteinases</topic><topic>Mice</topic><topic>Molecular docking</topic><topic>Molecular Docking Simulation</topic><topic>NF-kappa B - metabolism</topic><topic>NF-κB</topic><topic>NF-κB protein</topic><topic>Nitric oxide</topic><topic>Nitric-oxide synthase</topic><topic>Osteoarthritis</topic><topic>Osteoarthritis - drug therapy</topic><topic>Osteoarthritis - immunology</topic><topic>Osteoarthritis - pathology</topic><topic>Pain</topic><topic>Phosphatidylinositol 3-Kinases - metabolism</topic><topic>Physiological effects</topic><topic>PI3K</topic><topic>Preconditioning</topic><topic>Prostaglandin E2</topic><topic>Proto-Oncogene Proteins c-akt - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Signal Transduction - immunology</topic><topic>Thrombospondin</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumor necrosis factor-α</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>He, Linjie</creatorcontrib><creatorcontrib>Pan, Yinan</creatorcontrib><creatorcontrib>Yu, Jiapei</creatorcontrib><creatorcontrib>Wang, Ben</creatorcontrib><creatorcontrib>Dai, Gaole</creatorcontrib><creatorcontrib>Ying, Xiaozhou</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>He, Linjie</au><au>Pan, Yinan</au><au>Yu, Jiapei</au><au>Wang, Ben</au><au>Dai, Gaole</au><au>Ying, Xiaozhou</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Decursin alleviates the aggravation of osteoarthritis via inhibiting PI3K-Akt and NF-kB signal pathway</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2021-08</date><risdate>2021</risdate><volume>97</volume><spage>107657</spage><epage>107657</epage><pages>107657-107657</pages><artnum>107657</artnum><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>•Decursin could improve the progression of osteoarthritis by inhibiting inflammatory reaction.•The molecular docking analysis showed that DE has a strong binding affinity with the inhibitory targets of PI3K.•Decursin may be a potential agent in treatment of osteoarthritis. Osteoarthritis (OA) is a common joint disease that takes joint degeneration or aging as its pathological basis, and joint swelling, pain or dysfunction as its main clinical manifestations. Decursin (DE), the major active component isolated from Angelica gigas Nakai, has been demonstrated to possess anti-inflammatory effect in many diseases. But, the specific physiological mechanism of DE on OA is not clear yet. Therefore, the object of this study was to assess the therapeutic effect of DE on OA, and to explore its potential anti-inflammatory mechanisms. In vitro cell experiments, the inflammatory response in chondrocytes is mediated via interleukin-1β (IL-1β), which led to abnormal secretion of pro-inflammatory factors, such as prostaglandin E2 (PGE2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), cyclooxygenase-2 (COX-2), nitric oxide (NO) and inducible nitric oxide synthase (iNOS). These cytokines were all decreased by the preconditioning of DE in a dose-dependent form of 1, 5, and 10 µM. Moreover, DE could restrain IL-1β-mediated inflammatory reaction and the collapse of extracellular matrix (ECM) via reducing the secretion of ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) and MMPs (matrix metalloproteinases). In short, DE restrained IL-1β-mediated abnormal excitation of PI3K/AKT/NF-κB axis. Furthermore, molecular docking analysis showed that DE has a strong binding affinity with the inhibitory targets of PI3K. In vivo animal studies, DE treatment could helped to improve destruction of articular cartilage and decreased the serum inflammatory factor levels in an operationally induced mouse OA model. To sum up, these data obtained from the experiment indicate that DE has good prospects for the treatment of osteoarthritis.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33878544</pmid><doi>10.1016/j.intimp.2021.107657</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-0979-7207</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1567-5769
ispartof International immunopharmacology, 2021-08, Vol.97, p.107657-107657, Article 107657
issn 1567-5769
1878-1705
language eng
recordid cdi_proquest_miscellaneous_2516227198
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects 1-Phosphatidylinositol 3-kinase
ADAM protein
Aging
AKT protein
Animals
Anti-Inflammatory Agents - pharmacology
Anti-Inflammatory Agents - therapeutic use
Arthritis
Benzopyrans - pharmacology
Benzopyrans - therapeutic use
Biomedical materials
Butyrates - pharmacology
Butyrates - therapeutic use
Cartilage
Cartilage (articular)
Cartilage diseases
Cartilage, Articular - drug effects
Cartilage, Articular - immunology
Cartilage, Articular - pathology
Chondrocyte
Chondrocytes
Cyclooxygenase-2
Cytokines
Decursin
Degeneration
Disease Progression
Drug Evaluation, Preclinical
Extracellular matrix
Health services
Humans
IL-1β
In vivo methods and tests
Inflammatory
Inflammatory response
Interleukin 6
Interleukin-1beta - metabolism
Joint diseases
Male
Matrix metalloproteinase
Matrix metalloproteinases
Mice
Molecular docking
Molecular Docking Simulation
NF-kappa B - metabolism
NF-κB
NF-κB protein
Nitric oxide
Nitric-oxide synthase
Osteoarthritis
Osteoarthritis - drug therapy
Osteoarthritis - immunology
Osteoarthritis - pathology
Pain
Phosphatidylinositol 3-Kinases - metabolism
Physiological effects
PI3K
Preconditioning
Prostaglandin E2
Proto-Oncogene Proteins c-akt - metabolism
Signal Transduction - drug effects
Signal Transduction - immunology
Thrombospondin
Tumor necrosis factor-TNF
Tumor necrosis factor-α
title Decursin alleviates the aggravation of osteoarthritis via inhibiting PI3K-Akt and NF-kB signal pathway
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T22%3A05%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Decursin%20alleviates%20the%20aggravation%20of%20osteoarthritis%20via%20inhibiting%20PI3K-Akt%20and%20NF-kB%20signal%20pathway&rft.jtitle=International%20immunopharmacology&rft.au=He,%20Linjie&rft.date=2021-08&rft.volume=97&rft.spage=107657&rft.epage=107657&rft.pages=107657-107657&rft.artnum=107657&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2021.107657&rft_dat=%3Cproquest_cross%3E2568032473%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2568032473&rft_id=info:pmid/33878544&rft_els_id=S1567576921002939&rfr_iscdi=true